Free tool
FAERS Monitor: Redemplo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219947 or its brand name (Redemplo, Plozasiran Sodium). Reports on generic versions are filed under their own applications.
Reports
104
Serious
13
13% of reports
Hospitalization
11
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache21
- nausea20
- blood glucose increased15
- injection site pain7
- fatigue5
- feeling abnormal5
- hyperglycaemia5
- blood triglycerides increased4
- dizziness4
- drug ineffective4
- dyspnoea4
- abdominal discomfort3
- alanine aminotransferase increased3
- back pain3
- injection site bruising3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 104 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,055 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood triglycerides increasedSignal | 4 | 45.8 | 17.5 | 133 |
| hyperglycaemiaSignal | 5 | 27.8 | 11.8 | 104 |
| blood glucose increasedSignal | 15 | 16.1 | 10.1 | 199 |
| alanine aminotransferase increasedSignal | 3 | 9.9 | 3.2 | 16 |
| injection site bruisingSignal | 3 | 7.6 | 2.5 | 11 |
| headacheSignal | 21 | 6.8 | 4.6 | 101 |
| nauseaSignal | 20 | 5.1 | 3.4 | 65 |
| injection site painSignal | 7 | 4.6 | 2.3 | 17 |
| feeling abnormalSignal | 5 | 4.2 | 1.8 | 9 |
| abdominal discomfort | 3 | 3.6 | 1.2 | 3 |
| back pain | 3 | 2.6 | 0.9 | 2 |
| dizziness | 4 | 1.6 | 0.6 | 0 |
| dyspnoea | 4 | 1.4 | 0.5 | 0 |
| fatigue | 5 | 1.3 | 0.6 | 0 |
| drug ineffective | 4 | 0.6 | 0.2 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.